XTX Topco Ltd Invests $606,000 in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• XTX Topco Ltd has acquired 30,929 shares of Genmab A/S, valuing the purchase at approximately $606,000.
• Barclays PLC significantly increased its stake in Genmab A/S by 1,072.8% in the last quarter, now owning 2,498 shares valued at $52,000.
• Genmab A/S has received various ratings from analysts, including a consensus rating of "Moderate Buy" and a price target of $37.80.

XTX Topco Ltd bought a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,929 shares of the company's stock, valued at approximately $606,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GMAB. Barclays PLC increased its holdings in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Genmab A/S in the fourth quarter valued at approximately $60,000. Advisors Preferred LLC purchased a new stake in Genmab A/S in the first quarter valued at approximately $84,000. Aquatic Capital Management LLC purchased a new stake in Genmab A/S in the fourth quarter valued at approximately $114,000. Finally, Blue Trust Inc. raised its stake in Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after purchasing an additional 4,666 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Trading Down 5.6%

Shares of GMAB stock traded down $1.26 during trading hours on Friday, hitting $21.43. 1,745,722 shares of the company's stock were exchanged, compared to its average volume of 1,084,945. The company has a market capitalization of $13.75 billion, a PE ratio of 10.77, a PEG ratio of 6.89 and a beta of 0.95. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $27.94. The business's 50 day simple moving average is $21.74 and its 200-day simple moving average is $20.86.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.23%. Equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.